Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P.
Wei AH, et al. Among authors: hou jz.
Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856.
Blood. 2020.
PMID: 32219442
Free PMC article.
Clinical Trial.